Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. by Fossard, Gaëlle et al.
ORIGINAL ARTICLE
Role of up-front autologous stem-cell transplantation
in peripheral T-cell lymphoma for patients in
response after induction: an analysis of patients from
LYSA centers
G. Fossard1,2,3, F. Broussais1, I. Coelho4, S. Bailly5,6, E. Nicolas-Virelizier7, E. Toussaint8, C. Lancesseur9,
F. Le Bras10, E. Willems11, E. Tchernonog12, T. Chalopin13, R. Delarue14, R. Gressin15, A. Chauchet16,
E. Gyan13, G. Cartron12, C. Bonnet11, C. Haioun10, G. Damaj9, P. Gaulard10, L. Fornecker8, H. Ghesquie`res1,
O. Tournilhac5,6, M. Gomes da Silva4, R. Bouabdallah17, G. Salles1,2,3 & E. Bachy1,2,3*
1Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite; 2Claude Bernard Lyon 1 University, Lyon; 3Cancer Center of Lyon (CRCL), INSERM
U1052 – CNRS UMR5286, Lyon, France; 4Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal; 5Hematology and Cell Therapy Department,
Hoˆpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand; 6Clermont Auvergne University, Clermont-Ferrand; 7Hematology Department, Centre Leon Berard,
Lyon; 8Hematology Department, CHU de Strasbourg, Strasbourg; 9Hematology Institute, CHU de Caen, Caen; 10Hematology Department, CHU Henri Mondor,
Creteil, France; 11Hematology Department, CHU de Lie`ge, Lie`ge, Belgium; 12Hematology Department, CHU de Montpellier, Montpellier; 13Hematology Department,
CHU de Tours, Tours; 14Hematology Department, CHU Necker Enfants Malades, AP-HP, Paris; 15Hematology Department, CHU de Grenoble, Grenoble;
16Hematology Department, CHU de Besancon, Besancon; 17Hematology Department, Institut Paoli Calmette, Marseille, France
*Correspondence to: Dr Emmanuel Bachy, Hematology Department, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Be´nite Cedex, France.
Tel: þ33-478-86-43-02; Fax: þ33-478-86-43-55; E-mail: emmanuel.bachy@chu-lyon.fr
Note: This study was previously presented in part in oral sessions at the 14th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland,
14–17 June 2017.
Background: Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to the rarity and the heterogeneity of
PTCL, no consensus has been achieved regarding even the type of first-line treatment. The benefit of autologous stem-cell
transplantation (ASCT) is, therefore, still intensely debated.
Patients and methods: In the absence of randomized trials addressing the role of ASCT, we performed a large multicentric
retrospective study and used both a multivariate proportional hazard model and a propensity score matching approach to
correct for sample selection bias between patients allocated or not to ASCT in intention-to-treat (ITT).
Results: Among 527 patients screened from 14 centers in France, Belgium and Portugal, a final cohort of 269 patients
65 years old with PTCL-not otherwise specified (NOS) (N¼ 78, 29%), angioimmunoblastic T-cell lymphoma (AITL) (N¼ 123,
46%) and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-ALCL) (N¼ 68, 25%) with partial (N¼ 52,
19%) or complete responses (N¼ 217, 81%) after induction was identified and information about treatment allocation was
carefully collected before therapy initiation from medical records. One hundred and thirty-four patients were allocated to ASCT
in ITT and 135 were not. Neither the Cox multivariate model (HR¼ 1.02; 95% CI: 0.69–1.50 for PFS and HR¼ 1.08; 95% CI: 0.68–
1.69 for OS) nor the propensity score analysis after stringent matching for potential confounding factors (logrank P¼ 0.90 and
0.66 for PFS and OS, respectively) found a survival advantage in favor of ASCT as a consolidation procedure for patients in
response after induction. Subgroup analyses did not reveal any further difference for patients according to response status,
stage disease or risk category.
Conclusions: The present data do not support the use of ASCT for up-front consolidation for all patients with PTCL-NOS, AITL,
or ALK-ALCL with partial or complete response after induction.
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Introduction
Peripheral T-cell lymphoma (PTCL) encompasses a broad
range of post-thymic (i.e. mature) subentities as defined by the
2008 WHO classification [1] and its recent revised version [2].
The most common entities are PTCL not otherwise specified
(NOS) or angioimmunoblastic T-cell lymphoma (AITL), each
representing approximately 20%–25% of mature T- and NK/
T-cell lymphomas according to the International PTCL project
and recent reports [3–6]. Compared with their B-cell counter-
parts, most PTCLs confer dismal prognosis. In fact, except for
anaplastic lymphoma kinase (ALK)-positive anaplastic large
cell lymphoma (ALCL), 10-year overall survival (OS) for
patients with PTCLs barely exceeds 15% [4]. Given the infre-
quency and the heterogeneity of these malignancies, no real
consensus on first-line treatment has been established for
most PTCLs [7]. Most medical teams worldwide use a cyclo-
phosphamide, doxorubicin, vincristine and prednisone
(CHOP)-based regimen because no other combination has
demonstrated clear superiority over this regimen [4, 8]. The
addition of etoposide might be beneficial, at least for a subset
of young patients with normal lactate dehydrogenase (LDH)
values [9, 10]. Prognosis using this approach remains poor, as
confirmed by a meta-analysis of 2815 patients treated with a
CHOP or CHOP-like regimen, which found a 5-year OS of
38.5% for all PTCLs [11].
Furthermore, the place of autologous stem-cell transplanta-
tion (ASCT) as a consolidation procedure for first-line patients
achieving a partial or complete response (PR and CR, respec-
tively) is still highly debated [12–14]. Several nonrandomized
prospective studies demonstrated consistent results regarding
the impact of autologous stem transplantation in the first-line
setting (see online-only extended bibliography). The number of
patients with PTCLs enrolled in those studies varied from 26 to
166, and ALKþALCL patients were excluded from most of
them. Apart from prospective studies, most series supporting
the use of ASCT in first-line settings were based on uncontrolled
retrospective data (see online-only extended bibliography).
Furthermore, they were highly heterogeneous with respect to
line of therapy (first or subsequent), histology subtype (usually
without precision regarding ALK status) and patient selection
(only patients undergoing the procedure were included in most
of them). All studies suffer from both positive and negative
biases since patients undergoing ASCT are usually fitter,
younger and in response to induction regimen but present
with more aggressive disease features than patients not under-
going ASCT. The precise role of stem-cell transplantation for
PTCLs, therefore, remains largely unknown in front-line set-
tings, mainly due to inherent patient selection bias and low
numbers of patients.
The lack of any randomized data to address the precise role
of autologous transplantation in first-line therapy for young
patients with PTCL-NOS, ALK-ALCL and AITL prompted us
to conduct a large multicentric and international retrospective
study. Only young patients (i.e. <65 years) in partial or com-
plete response were considered to mitigate the strongest con-
founding bias in all previously published prospective and
retrospective studies, that is the response achievement and
quality after induction.
Methods
Patients, data collection and response assessment
All patients between 18 and 65 years old diagnosed with ALK-ALCL,
PTCL-NOS or AITL between 1 January 2000 and 31 December 2015,
from 14 centers in France, Belgium and Portugal were identified from
local databases. Histological diagnosis was made by expert hematopa-
thologists. Treatment choice for induction and consolidation (ASCT or
observation) was made by local physicians in each center. There was no
institutional policy as to whether all patients from a same center should
receive ASCT or not. Data were retrospectively collected from medical
records in all centers. The intention-to-treat (ITT) decision for ASCT at
the time of therapy initiation was abstracted either from the initial medi-
cal report or the report from the multidisciplinary meeting before the
start of treatment. Importantly, ITT could be precisely determined for all
patients in the study before treatment initiation. The response assessment
was determined at the end of induction treatment based on the
International Working Group (IWG) criteria [15]. Since ASCT proce-
dure arrangement usually takes a few weeks to proceed, only patients
with a response duration lasting at least 3 months were considered as res-
ponders in the study. For patients with bone marrow involvement at
diagnosis, all patients except two had a new biopsy at the end of induction
to confirm or not the complete response status. If no marrow reassess-
ment was performed, the patient was considered in partial response only
(PR). Computed tomography (CT) scanner images and tumor response
were analyzed and assessed by local radiologists. No patient with partial
response received further treatment.
Statistical analysis
Chi-square or Fischer’s exact tests were used for statistical comparison of
categorical variables. Age distributions were compared using the Mann–
Whitney test. OS was calculated from the date of induction therapy until
either the date of death from any cause or the date of the last contact.
Progression-free survival (PFS) was measured from the date of induction
therapy initiation to either the date of death from any cause, the date of
progression or the date of last contact. Since subsequent treatment was
administered only in case of disease progression, event-free survival
(EFS) considering new treatment as an event was identical to PFS.
Survival curves were constructed using the Kaplan–Meier method and
were compared using the log-rank test [16]. The Cox proportional haz-
ards regression model was used to assess the effect of multiple variables
on OS and PFS [17]. All imbalanced parameters between the ASCT ITT
and no-ITT groups were incorporated into the model along with age and
histology subtypes. Propensity score matching (PSM) was carried out
with a 1 : 1 case : control ratio. The nearest-neighbor matching method
was used with a stringent caliper equal to 0.05 of the standard deviation
of the logit of the PSM (MatchIt Package version 2.4-21, R software).
PSM analysis accounted for age, LDH, PS, stage, B symptoms, histology,
induction regimen and response quality for matching. All other tests
were two-sided, and a P-level of 0.05 was considered as statistically signif-
icant. Analyses were carried out using SAS version 9.2 (SAS Institute Inc.,
Cary, NC), R version 3.3.1 (R Foundation for Statistical Computing,
Vienna, Austria, https://www.R-project.org/) and SPSS version 20 for
Mac (SPSS, Chicago, IL).
Results
Patient characteristics
From the initial population of 527 patients, 269 of 471 patients
with evaluable response status at the end of induction were res-
ponders (i.e. 57%) and were thus taken into account in the
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present study. The final study population comprised 269 young
(i.e.65 years old) patients with CR or PR at the end of the induc-
tion treatment (Figure 1). A vast majority of them (81%) were in
CR. Twenty-nine percent of patients had PTCL-NOS (N¼ 78),
46% had AITL (N¼ 123) and 25% had ALK-ALCL (N¼ 68). By
ITT, ASCT was chosen by a local physician as a consolidation pro-
cedure for 50% of patients (N¼ 134). Eventually, 22 patients did
not undergo ASCT. Among them, there were six stem-cell collec-
tion failures. Eight patients who had responded for at least
3 months as per inclusion criteria relapsed just before starting con-
ditioning regimen. The absence of a global consensus and recom-
mendation regarding the use of up-front ASCT in PTCL was
reflected by the heterogeneity of actual practice according to
period of diagnosis and the hematology center (supplementary
Figure S1, available at Annals of Oncology online). Patient charac-
teristics according to ASCT ITT are summarized in Table 1. Briefly
and as expected, patients who were allocated to ASCT in ITT by
local physician presented with more aggressive disease. Hence, B
symptoms, advanced stage disease, extranodal involvement and
elevated LDH were observed significantly more frequently and
resulted in higher age-adjusted International Prognostic Index
(aaIPI) and lower CR rates in this patient group (P¼ 0.002 and
P¼ 0.028, respectively). No significant difference was noted
concerning patient age, histology subtype, bone marrow involve-
ment, induction regimen, or PIT. Of note, positron emission
tomography–computed tomography (PET-CT) scanner was
performed for 119 patients out of 269. All patients except one con-
sidered in CR based on the IWG [15] criteria (N¼ 101) were PET-
negative. Among the 18 patients evaluated by PET-CT scanner and
in PR only using standard CT, 5 were reclassified as in CR. Median
time from response assessment to ASCT was 1.5 months (range,
0.2–4.9) and conditioning regimen was BEAM for all patients
except four (cyclophosphamide and total body irradiation, three
patients; CCNU instead of BCNU for one patient).
Survival
Median follow-up for surviving patients (N¼ 163) was 4.8 years.
Among those, only eight patients had a follow-up shorter than
1 year. The median PFS was 3.7 years, and the median OS was
Initial population (n=527)
Inclusion criteria:
Histology (PTCL-NOS, AITL or ALK-ALCL)
Age (<65 years)
Stable or progressive disease (n=202)
Lost to follow-up (n=23)
Study population (n=269)
PTCL-NOS (n=78)
AITL (n=123)
ALK-ALCL (n=68)
PTCL-NOS (n=46)
AITL (n=57)
ALK-ALCL (n=31)
Allogeneic stem cell transplantation in first remission (n=15)
No date of therapy initiation (n=2)
Not evaluable, untreated, corticosteroids only (n=16)
Period (1/1/2000 to 12/31/2015)
ASCT ITT (n=134)
PTCL-NOS (n=32)
AITL (n=66)
ALK-ALCL (n=37)
No ASCT ITT (n=135)
ASCT actually performed
(n=112)
ASCT not performed (n=22) ASCT actually performed
(n=2)
ASCT not performed (n=133)
Physician choice given
partial response only
Stem cell collection failure (n=6)
Relapse before ASCT (n=8)
Toxicity during induction (n=2)
Patient refusal (n=3)
Others (n=3)
Figure 1. Study ﬂowchart.
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Table 1. Patient characteristics according to ASCT in intention-to-treat
N (%)a
Missing
Data (N)
ASCT ITT No
(N5 135)
ASCT ITT Yes
(N5 134)
P
Age, years 0 0.25
Mean (minimum–maximum) 53 (19–65) 52 (19–66)
Histology 0 0.15
PTCL-NOS 32 (24) 46 (34)
AITL 66 (49) 57 (43)
ALK-ALCL 37 (27) 31 (23)
Sex 0 0.031
Female 48 (36) 65 (48)
Male 87 (64) 69 (51)
ECOG score 4 0.39
0-1 105 (80) 100 (75)
2-4 27 (20) 33 (25)
B symptoms 18 0.001
no 70 (55) 42 (34)
yes 58 (45) 81 (66)
Stage 1 <0.001
I–II 35 (26) 9 (7)
III–IV 100 (74) 124 (93)
Bone marrow involvement 4 0.85
no 90 (67) 88 (68)
yes 45 (33) 42 (32)
Extranodal involvement 2 0.038
No 62 (46) 45 (34)
Yes 72 (54) 88 (66)
LDH 12 0.009
UNL 58 (45) 38 (30)
>UNL 70 (55) 91 (70)
aaIPI 15 0.002
0–1 62 (49) 38 (30)
2–3 65 (51) 89 (70)
PIT 15 0.10
0–1 69 (54) 56 (44)
2–4 58 (46) 71 (56)
Response to induction 0 0.028
CR 116 (86) 101 (75)
PR 19 (14) 33 (25)
Time from response evaluation to ASCTb, yrs 0
Median (minimum–maximum) NA 1.5 (0.2–4.9) NA
Treatment 0 0.14
CHOP-like or CHOEPc 98 (73) 108 (81)
ACVBP or COPADM 30 (22) 24 (18)
Othersd 7 (5) 2 (1)
aExcept for age (mean and range).
bWhen ASCT was actually performed.
cCHOP every 2 or 3weeks (n¼ 151), CHOPþ rituximab for some patients with AITL (n¼ 21), CHOPþ alemtuzumab (n¼ 4) and CHOPþ romidepsin (n¼ 6);
CHOEP (n¼ 24 patients).
dOther regimens are DHAP (aracytine- and platine-based regimen), VIP-rABVD8 and CVP (CHOP-like regimen without anthracyclines).
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone;
ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone; COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin and
methotrexate; ASCT, autologous stem-cell transplantation; ITT, intention-to-treat; PTCL-NOS, peripheral T-cell lymphoma not otherwise speciﬁed; AITL,
angioimmunoblastic T-cell lymphoma; ALK-ALCL, anaplastic large cell lymphoma kinase-negative lymphoma; ECOG, Eastern Cooperative Oncology Group;
LDH, lactate dehydrogenase; UNL, upper normal limit; aaIPI, age-adjusted international prognostic index; PIT, prognostic index for T-cell lymphoma; CR,
complete response; PR, partial response; NA, not applicable.
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8.4 years for the entire cohort (Figure 2A and B). At 5 years, PFS
was 45.0% (95% confidence interval (CI): 37.8% to 50.6%), and
OS was 60.4% (95% CI: 53.6% to 66.5%). Patients with ALK-
ALCL experienced a slightly longer time to progression compared
with patients with PTCL-NOS or AITL, although the difference
did not reach significant difference (Figure 2C). No OS difference
was observed according to histology subtype (Figure 2D).
Multivariate analysis
To account for disease severity imbalances between ITT sub-
groups, a multivariate analysis using a Cox proportional hazard
ratio regression model was performed. Based on 240 observations
with fully available data, it demonstrated that only remission sta-
tus (CR versus PR) at the end of induction was associated with
significantly prolonged PFS and OS (Table 2). Patient allocation
to ASCT in ITT was not associated with an improved outcome
(HR¼ 1.02, 95% CI: 0.69–1.50 for PFS and HR¼ 1.08, 95% CI:
0.68–1.69 for OS). A model where aaIPI was replaced by its indi-
vidual variables gave similar results (data not shown).
Propensity score matching analysis
Patient age, disease severity and induction regimen are known
potential confounding factors undermining the formal assessment
of ASCT in first-line settings. To strengthen results from the
multivariate Cox model, another approach using a propensity score
matching analysis was performed based on the conditional probabil-
ity of assigning patients to ASCT based on age, LDH, PS, stage, B
symptoms, histology, induction regimen and response quality. The
final matched population comprised 73 patients in each group with
balanced propensity scores (supplementary Figure S2, available at
Annals of Oncology online) and comparable baseline characteristics
and response quality (Table 3). Only proportion of patients with
bone marrow involvement was nearly significantly different
(P¼ 0.06) but with a higher rate in the no-ASCT group.
No outcome difference was observed between the two groups
regarding either PFS or OS (P¼ 0.90 and 0.66, respectively,
Figure 3). At 5 years, PFS was 40.5% (95% CI: 28.0% to 52.6%) and
46.3% (95% CI: 34.1% to 57.6%); OS was 60.4% (95% CI: 46.7% to
71.6%) and 59.2% (46.1% to 70.1%) among patients without or
with ASCT planned according to ITT, respectively. No difference
according to the use of up-front ASCT in ITT was further noted
when patients with advanced stage disease (III or IV), with aaIPI> 1
or reaching a PR only at the end of induction were considered
(supplementary Figure S3, available at Annals of Oncology online for
survival according to ASCT-ITT and response status).
Causes of death
One hundred and six patients died during the follow-up.
The main cause of death was disease progression (N¼ 87, 82%),
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Figure 2. Survival of patients in response after induction. (A) Progression-free survival. (B) Overall survival. (C) Progression-free survival accord-
ing to histological subtype. (D) Overall survival according to histological subtype.
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followed by fist-line treatment related mortality defined by death
in first remission (N¼ 12, 11%), death in subsequent remission
(N¼ 5, 5%) and unknown causes (N¼ 2, 2%). By ITT, no signifi-
cant difference in terms of cause of death was observed between
patients allocated to the ASCT group compared with the no-
ASCT group (P¼ 0.09, supplementary Table S1, available at
Annals of Oncology online). No further difference was observed
when the group of patients actually receiving the ASCT proce-
dure was considered compared with those who did not under-
went ASCT (“per protocol” comparison). Four second
malignancies were observed without any differences between
sub-groups (supplementary Table S1, available at Annals of
Oncology online). The absence of benefit for patients receiving
ASCT in first remission was therefore not due to an increased tox-
icity related to the procedure.
Discussion
In the absence of a randomized trial, no definitive agreement has
been reached on the role of ASCT as an up-front consolidation
strategy for patients with ALK- ALCL, AITL or PTCL-NOS in PR
or CR after induction. A summary of selected prospective and ret-
rospective publications specifically addressing the role of ASCT in
PTCL in first line is presented in supplementary Table S2, available
at Annals of Oncology online. ESMO recommendations and recent
guidelines from a committee of the American Society for Blood
and Marrow Transplantation currently propose ASCT as first-line
therapy for transplant-eligible patients [18, 19]. NCCN guidelines
(version 2.2017) recommend ASCT or observation for patients in
CR and additional treatment followed by ASCT or allogeneic
stem-cell transplantation for patients with PR. Based on a large
multicenter and international cohort of patients with PR or CR
after induction, we did not detect any survival advantage of ASCT
over observation for patients achieving at least a partial response
after induction.
The role of up-front ASCT as a consolidation therapy for
patients with PTCL has been a critical question for years. Despite
many prospective and retrospective studies addressing the issue,
no definitive answer or broad consensus has been reached due to
the lack of controlled trial (see online-only extended bibliogra-
phy). A formal comparison between approaches is hampered by
the fact that patients allocated to ASCT often present with more
aggressive disease at diagnosis, while transplant-eligible patients
are usually fitter or younger. Both retrospective and prospective
uncontrolled published studies have suffered from several caveats
precluding unbiased conclusions on the role of up-front ASCT.
Hence, most retrospective studies did not assess ITT ASCT
assignment but only included patients undergoing the procedure.
In such studies, long-term survival of transplanted patients is
usually not compared with survival of non-transplanted respond-
ers. In prospective uncontrolled studies, transplant-eligible
patients are considered only, rendering any comparison with his-
torical cohorts merely speculative.
To the best of our knowledge, this is the largest analysis carried
out to evaluate the role of up-front ASCT in responder patients
with PTCL. A recently published real-world data analysis from
Table 2. Multivariate Cox proportional hazard ratio regression model
PFSa OSa
HR 95% CI P HR 95% CI P
B symptoms
Yes (versus no) 1.18 0.78–1.79 0.41 0.89 0.55–1.44 0.65
Histology
AITL (versus PTCL-NOS) 0.97 0.62–1.51 0.89 0.97 0.58–1.63 0.92
ALK- ALCL (versus PTCL-NOS) 0.74 0.43–1.25 0.26 0.79 0.43–1.46 0.46
Age, years
Continuous parameter 0.99 0.97–1.01 0.56 1.01 0.99–1.04 0.15
Sex
Male (versus female) 1.42 0.97–2.06 0.07 1.21 0.79–1.87 0.37
aaIPI
1 (versus 0) 1.31 0.61–2.84 0.48 1.27 0.50–3.20 0.60
2 (versus 0) 1.53 0.71–3.29 0.27 1.45 0.57–3.66 0.42
3 (versus 0) 1.72 0.72–4.09 0.21 1.83 0.65–5.13 0.24
Response to induction
PR (versus CR) 1.86 1.22–2.84 0.003 2.04 1.28–3.25 0.002
ASCT ITT
Yes (versus no) 1.02 0.69–1.50 0.89 1.08 0.68–1.69 0.74
aModels carried out on 240 observations with fully available parameters.
PFS, progression-free survival; OS, overall survival; AITL, angioimmunoblastic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma-not otherwise speci-
ﬁed; ALK-ALCL, anaplastic large cell lymphoma kinase-negative lymphoma; aaIPI, age-adjusted international prognostic index; PR, partial response; CR,
complete response; ASCT ITT, autologous stem-cell transplantation in intention-to-treat; HR, hazard ratio; CI, conﬁdence interval.
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the Swedish Lymphoma Registry found prolonged OS and PFS
for transplanted patients with PTCL-NOS, AITL, ALK-ALCL and
enteropathy-associated T-cell lymphoma after adjustment for
potentially confounding factors in multivariate analysis [9].
However, the group of patients retrospectively allocated to the
non-ASCT category in ITT might include a higher proportion of
patients with early progression for whom ASCT could not have
been considered. No adjustment on response status, the strongest
bias in assessing the role of ASCT, was therefore conducted to
rule out any imbalance between subgroups. Actually, a recently
published series partially based on the same real-word registry
did not find any survival advantage for ASCT in uni- or multi-
variate analysis when patients in CR only were considered [20].
In the present study, since only responders were enrolled
Table 3. Characteristics of the propensity score matched population
N (%)a
Missing
data (N)
ASCT ITT ASCT ITT P
No (N5 73) Yes (N5 73)
Age, years 0 0.51
Mean (minimum–maximum) 55 (19–65) 55 (29–66)
Histology 0 0.41
PTCL-NOS 19 (26) 19 (26)
AITL 43 (59) 37 (51)
ALK-ALCL 11 (15) 17 (23)
Sex 0 0.09
Female 44 (60) 33 (45)
Male 29 (40) 40 (55)
ECOG score 0 0.85
0–1 53 (73) 51 (70)
2–4 20 (27) 22 (30)
B symptoms 0 0.73
No 26 (36) 29 (40)
Yes 47 (64) 44 (60)
Stage 0 1.00
I–II 5 (7) 6 (8)
III–IV 68 (93) 67 (92)
Bone marrow involvement 3 0.06
No 39 (53) 49 (70)
Yes 34 (47) 21 (30)
Extranodal involvement 0 0.86
No 24 (33) 26 (36)
Yes 49 (67) 47 (64)
LDH 0 0.59
UNL 25 (34) 21 (29)
>UNL 48 (66) 52 (71)
aaIPI 0 0.85
0–1 24 (33) 22 (30)
2–3 49 (67) 51 (69)
PIT 0 0.73
0–1 30 (41) 33 (45)
2–4 43 (59) 40 (55)
Response to induction 0 1.00
CR 62 (85) 61 (84)
PR 11 (15) 12 (16)
Treatment 0 0.12
CHOP-like or CHOEP 55 (75) 63 (86)
ACVBP or COPADM 16 (22) 10 (14)
Others 2 (3) 0 (0)
For abbreviations, see Table 1.
aExcept for age (mean and range).
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(ensuring that all patients survived at least until the end-of-
induction without the need for a landmark time analysis), no selec-
tion bias undermined the outcome assessment. Supporting the sig-
nificance of response quality in PTCL, CR achievement prevailed
over any baseline prognosis factors in the multivariate model. In
line with the present data, a recently published large retrospective
multicenter US study showed that the survival advantage conferred
by ASCT in a univariate analysis vanished after the adjustment for
potentially confounding factors (i.e. CR to initial chemotherapy,
stage, LDH, and hypoalbuminemia) [21].
Overall, 5-year PFS and OS for responders were 45% and 60%,
respectively, without a significant difference according to ASCT
in ITT. In PTCL-NOS and AITL, 5-year PFS and OS rates have
been previously reported not to exceed 20% and 35%, respec-
tively [4], confirming that primary refractoriness is one of the
major concerns for patients with PTCL. Importantly, 57% of
patients from the initially screened population were in CR (46%)
or PR (11%) at the end of induction and were included in the
study. This is in line with previously published studies where
ALKþALCL patients were excluded: 62% of ORR for the
randomized study from Simon et al. [8] (<5% of patients with
ALKþALCL), 59% of ORR in the prospective series from
Mercadal et al. [22] or 52% of CR in the retrospective work from
Yam et al. [23]. Furthermore, one of the main inclusion criteria
of the study was that response had to last at least 3 months to be
considered. So, patients with very early relapse after induction
were considered as primary refractory and were not enrolled in
the study. This ensured that there was sufficient time to perform
transplantation in the ASCT-ITT group to limit a potential bias
disfavoring the procedure (median time from response assess-
ment to ASCT was therefore 1.5 months). This could also explain
why the proportion of responders is slightly lower than reported
in other studies [24, 25]. Supporting the view that prognosis in
PTCL is related to response to induction and not to the ASCT
procedure itself, a recently published study from Tobinai and col-
leagues showed that 45% of patients<65 years in CR after induc-
tion were alive without disease at 5 years [26]. The figure is
perfectly identical to the 45% 5-year PFS in our series of patients
whether they were allocated to ASCT or not in ITT.
The present work suffers from some of the typical drawbacks of
retrospective data collection. These disadvantages include the
absence of histologic diagnosis and radiologic review, although
there is no a priori reason this could favor a group of patients
over the other. The extended inclusion period, the differing dura-
tion of follow-up and the lack of sufficient power to detect a lim-
ited outcome difference between ASCT and no further
consolidation treatment have to be further acknowledged.
Additionally, matching or statistical adjustment techniques can-
not account for all confounding parameters and biases. We can-
not rule out that other features of aggressive disease were not
fully captured by baseline characteristics or response quality.
Notably, since only 24 patients received etoposide in addition to
CHOP as an induction regimen, the specific role of the drug could
not be statistically assessed in the present study. In addition, lim-
ited number of patients in each histological subgroup precluded
reasonable evaluation of ASCT according to subtypes. Lastly, PET-
CT was performed in roughly one-third of the cohort with a low
number of discordant cases therefore precluding an analysis based
on PET-CT response criteria compared with CT assessment.
It is generally acknowledged that ASCT can provide a long-
term control of PTCL with a survival plateau after 5 years.
However, the present study demonstrates that such a plateau can
be achieved without the need for consolidation treatment of
patients with a response following the induction regimen (Figure
3B). Moreover, all patient data were individually collected. The
treatment allocation was determined before induction therapy
was started, and the sample size was substantial, with homogene-
ous histological subtypes (PTCL-NOS versus AITL versus ALK-
ALCL) and response statuses (PR or CR) underlying the strong
quality control of the current study.
Overall, and in consideration of the study limitations, the data
presented in this study do not support the use of ASCT as a con-
solidation strategy for all responding patients with PTCL-NOS,
AITL or ALK-ALCL in first line. Further study is needed to
precisely evaluate if a specific subgroup like patients with PET-
defined PR, specific histologic or molecular subtype, might
benefit from the procedure. Moreover, given the flaws of any ret-
rospective data collection, the economic burden associated to
ASCT in PTCL [27] and the absence of any consensus over the
procedure, a large collaborative randomized trial should be
undertaken to allow for a definitive answer.
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Figure 3. Propensity score matching survival analysis of patients in
response after induction. (A) Progression-free survival of patients in
the matched subset cohort. (B) Overall survival of patients in the
matched subset cohort.
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